You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameHydroxychloroquine
Accession NumberDB01611
TypeSmall Molecule
GroupsApproved
Description

A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites.

Structure
Thumb
Synonyms
(+-)-Hydroxychloroquine
(±)-hydroxychloroquine
2-((4-((7-chloro-4-Quinolyl)amino)pentyl)ethylamino)ethanol
2-(N-(4-(7-Chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol
7-chloro-4-(4-(Ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline
7-chloro-4-(4-(N-Ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino)quinoline
7-chloro-4-[4-(N-Ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino]quinoline
7-chloro-4-[5-(N-Ethyl-N-2-hydroxyethylamino)-2-pentyl]aminoquinoline
Hidroxicloroquina
Hydroxychloroquinum
NSC4375
Oxichlorochine
Oxichloroquine
Polirreumin
External Identifiers Not Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Hydroxychloroquine Sulfatetablet200 mg/1oralAvera Mc Kennan Hospital2015-03-24Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Hydroxychloroquine Sulfatetablet200 mg/1oralPrasco Laboratories2014-12-12Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Mint-hydroxychloroquinetablet200 mgoralMint Pharmaceuticals Inc2014-06-10Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Mylan-hydroxychloroquinetablet200 mgoralMylan Pharmaceuticals Ulc2004-05-21Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Nu-hydroxyquinetablet200 mgoralNu Pharm IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Plaqueniltablet, film coated200 mg/1oralSanofi Aventis U.S. Llc1955-04-18Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Plaqueniltablet200 mgoralSanofi Aventis Canada Inc1957-12-31Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Plaqueniltablet200 mg/1oralCarilion Materials Management2013-06-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Plaqueniltablet200 mg/1oralConcordia Pharmaceuticals Inc.2013-06-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Plaqueniltablet200 mg/1oralCovis Pharmaceuticals Inc2013-06-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
PMS-hydroxychloroquinetablet200 mgoralPharmascience IncNot applicableNot applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Pro-hydroxyquine - 200tablet200 mgoralPro Doc Limitee2008-07-29Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-hydroxyquinetablet200 mgoralApotex Inc2002-12-13Not applicableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Hydroxychloroquine Sulfatetablet, film coated200 mg/1oralRanbaxy Pharmaceuticals Inc.2009-01-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Hydroxychloroquine Sulfatetablet, film coated200 mg/1oralWest ward Pharmaceutical Corp2007-08-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Hydroxychloroquine Sulfatetablet, film coated200 mg/1oralAidarex Pharmaceuticals LLC2009-01-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Hydroxychloroquine Sulfatetablet, film coated200 mg/1oralAvera Mc Kennan Hospital2015-08-31Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Hydroxychloroquine Sulfatetablet, film coated200 mg/1oralCardinal Health1995-11-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Hydroxychloroquine Sulfatetablet, film coated200 mg/1oralRebel Distributors Corp2009-01-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Hydroxychloroquine Sulfatetablet, film coated200 mg/1oralZydus Pharmaceuticals (USA) Inc.2008-01-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Hydroxychloroquine Sulfatetablet, film coated200 mg/1oralCardinal Health2008-08-05Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Hydroxychloroquine Sulfatetablet, film coated200 mg/1oralBlenheim Pharmacal, Inc.2013-12-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Hydroxychloroquine Sulfatetablet, film coated200 mg/1oralAmerican Health Packaging2008-08-05Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Hydroxychloroquine Sulfatetablet, film coated200 mg/1oralPhysicians Total Care, Inc.1996-07-09Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Hydroxychloroquine Sulfatetablet, film coated200 mg/1oralMajor Pharmaceuticals1995-11-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Hydroxychloroquine Sulfatetablet, film coated200 mg/1oralDispensing Solutions, Inc.2009-01-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Hydroxychloroquine Sulfatetablet, film coated200 mg/1oralOhm Laboratories Inc.2009-01-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Hydroxychloroquine Sulfatetablet, film coated200 mg/1oralSandoz Inc1995-11-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Hydroxychloroquine Sulfatetablet, film coated200 mg/1oralCadila Healthcare Limited2008-01-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Hydroxychloroquine Sulfatetablet200 mg/1oralREMEDYREPACK INC.2011-04-13Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Hydroxychloroquine Sulfatetablet, coated200 mg/1oralWatson Laboratories, Inc.1995-11-30Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Hydroxychloroquine Sulfatetablet, film coated200 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2008-01-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Hydroxychloroquine Sulfatetablet, film coated200 mg/1oralNorthstar Rx LLC2015-12-18Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Hydroxychloroquine Sulfatetablet200 mg/1oralAphena Pharma Solutions Tennessee, Llc2012-02-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Hydroxychloroquine Sulfatetablet, film coated200 mg/1oralDIRECT RX2014-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Hydroxychloroquine Sulfatetablet, film coated200 mg/1oralbryant ranch prepack2009-01-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Hydroxychloroquine Sulfatetablet, film coated200 mg/1enteralMylan Pharmaceuticals Inc.1998-06-18Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Hydroxychloroquine Sulfatetablet, film coated200 mg/1oralAv Kare, Inc.2014-05-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Hydroxychloroquine Sulfatetablet200 mg/1oralAv Kare, Inc.2012-02-292015-12-29Us 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Hydroxychloroquine Sulfatetablet, film coated200 mg/1oralGolden State Medical Supply, Inc.2007-08-15Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International Brands
NameCompany
AxokineAstraZeneca
DolquineInmunosyn
HCQSMedigroup
PolirreuminTRB
QuensylSanofi
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Hydroxychloroquine sulfate
Thumb
  • InChI Key: JCBIVZZPXRZKTI-UHFFFAOYNA-N
  • Monoisotopic Mass: 433.143819418
  • Average Mass: 433.95
DBSALT000096
Categories
UNII4QWG6N8QKH
CAS number118-42-3
WeightAverage: 335.872
Monoisotopic: 335.176440176
Chemical FormulaC18H26ClN3O
InChI KeyInChIKey=XXSMGPRMXLTPCZ-UHFFFAOYSA-N
InChI
InChI=1S/C18H26ClN3O/c1-3-22(11-12-23)10-4-5-14(2)21-17-8-9-20-18-13-15(19)6-7-16(17)18/h6-9,13-14,23H,3-5,10-12H2,1-2H3,(H,20,21)
IUPAC Name
2-({4-[(7-chloroquinolin-4-yl)amino]pentyl}(ethyl)amino)ethan-1-ol
SMILES
CCN(CCO)CCCC(C)NC1=C2C=CC(Cl)=CC2=NC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as aminoquinolines and derivatives. These are organic compounds containing an amino group attached to a quinoline ring system.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassQuinolines and derivatives
Sub ClassAminoquinolines and derivatives
Direct ParentAminoquinolines and derivatives
Alternative Parents
Substituents
  • Chloroquinoline
  • Aminoquinoline
  • Secondary aliphatic/aromatic amine
  • Chlorobenzene
  • Aminopyridine
  • Benzenoid
  • Pyridine
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • Tertiary aliphatic amine
  • Tertiary amine
  • 1,2-aminoalcohol
  • Azacycle
  • Secondary amine
  • Alkanolamine
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the suppressive treatment and treatment of acute attacks of malaria due to Plasmodium vivax, P. malariae, P. ovale, and susceptible strains of P. falciparum. It is also indicated for the treatment of discoid and systemic lupus erythematosus, and rheumatoid arthritis.
PharmacodynamicsHydroxychloroquine possesses antimalarial properties and also exerts a beneficial effect in lupus erythematosus (chronic discoid or systemic) and acute or chronic rheumatoid arthritis. The precise mechanism of action is not known.
Mechanism of actionAlthough the exact mechanism of action is unknown, it may be based on ability of hydroxychloroquine to bind to and alter DNA. Hydroxychloroquine has also has been found to be taken up into the acidic food vacuoles of the parasite in the erythrocyte. This increases the pH of the acid vesicles, interfering with vesicle functions and possibly inhibiting phospholipid metabolism. In suppressive treatment, hydroxychloroquine inhibits the erythrocytic stage of development of plasmodia. In acute attacks of malaria, it interrupts erythrocytic schizogony of the parasite. Its ability to concentrate in parasitized erythrocytes may account for their selective toxicity against the erythrocytic stages of plasmodial infection. As an antirheumatic, hydroxychloroquine is thought to act as a mild immunosuppressant, inhibiting the production of rheumatoid factor and acute phase reactants. It also accumulates in white blood cells, stabilizing lysosomal membranes and inhibiting the activity of many enzymes, including collagenase and the proteases that cause cartilage breakdown.
AbsorptionVery rapidly and completely absorbed following oral administration.
Volume of distributionNot Available
Protein bindingApproximately 45%.
Metabolism

Partially hepatic, to active de-ethylated metabolites.

Route of eliminationNot Available
Half lifeTerminal elimination half-life In blood is approximately 50 days. In plasma it is approximately 32 days.
ClearanceNot Available
ToxicitySymptoms of overdose include headache, drowsiness, visual disturbances, cardiovascular collapse, and convulsions, followed by sudden and early respiratory and cardiac arrest. The electrocardiogram may reveal atrial standstill, nodal rhythm, prolonged intraventricular conduction time, and progressive bradycardia leading to ventricular fibrillation and/or arrest.
Affected organisms
  • Plasmodium
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9892
Blood Brain Barrier+0.5602
Caco-2 permeable-0.5154
P-glycoprotein substrateSubstrate0.8348
P-glycoprotein inhibitor INon-inhibitor0.7297
P-glycoprotein inhibitor IIInhibitor0.5106
Renal organic cation transporterNon-inhibitor0.5742
CYP450 2C9 substrateNon-substrate0.8239
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateNon-substrate0.5384
CYP450 1A2 substrateNon-inhibitor0.5864
CYP450 2C9 inhibitorNon-inhibitor0.8457
CYP450 2D6 inhibitorNon-inhibitor0.6111
CYP450 2C19 inhibitorNon-inhibitor0.8782
CYP450 3A4 inhibitorNon-inhibitor0.6287
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7058
Ames testAMES toxic0.6907
CarcinogenicityNon-carcinogens0.837
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6348 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6798
hERG inhibition (predictor II)Inhibitor0.7173
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tablet, coatedoral200 mg/1
Tablet, film coatedenteral200 mg/1
Tabletoral200 mg/1
Tabletoral200 mg
Tablet, film coatedoral200 mg/1
Prices
Unit descriptionCostUnit
Hydroxychloroquine sulf powder4.8USD g
Plaquenil 200 mg tablet3.14USD tablet
Hydroxychloroquine Sulfate 200 mg tablet1.28USD tablet
Hydroxychloroquine 200 mg tablet1.17USD tablet
Plaquenil Sulfate 200 mg Tablet0.66USD tablet
Apo-Hydroxyquine 200 mg Tablet0.35USD tablet
Mylan-Hydroxychloroquine 200 mg Tablet0.35USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point89-91U.S. Patent 2,546,658.
Predicted Properties
PropertyValueSource
Water Solubility0.0261 mg/mLALOGPS
logP3.87ALOGPS
logP2.89ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)15.59ChemAxon
pKa (Strongest Basic)9.76ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area48.39 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity97.97 m3·mol-1ChemAxon
Polarizability38.3 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
MSMass Spectrum (Electron Ionization)splash10-ezt9000000-7c193125680c0c9e276fView in MoNA
References
Synthesis Reference

U.S. Patent 2,546,658.

General ReferencesNot Available
External Links
ATC CodesP01BA02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AcepromazineThe serum concentration of Acepromazine can be increased when it is combined with Hydroxychloroquine.
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Hydroxychloroquine.
DapsoneThe risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Dapsone.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Hydroxychloroquine.
LumefantrineThe risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Lumefantrine.
MefloquineThe risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Mefloquine.
OxibendazoleThe serum concentration of Oxibendazole can be decreased when it is combined with Hydroxychloroquine.
QuinacrineThe serum concentration of Quinacrine can be decreased when it is combined with Hydroxychloroquine.
ThiabendazoleThe serum concentration of Thiabendazole can be decreased when it is combined with Hydroxychloroquine.
Food InteractionsNot Available

Targets

1. DNA

Kind: Nucleotide

Organism: Human

Pharmacological action: yes

Actions: cross-linking/alkylation

Components

Name UniProt ID Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Koranda FC: Antimalarials. J Am Acad Dermatol. 1981 Jun;4(6):650-5. Pubmed

2. Toll-like receptor 7

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
Toll-like receptor 7 Q9NYK1 Details

References:

  1. Sun S, Rao NL, Venable J, Thurmond R, Karlsson L: TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets. 2007 Dec;6(4):223-35. Pubmed
  2. Trevani AS, Chorny A, Salamone G, Vermeulen M, Gamberale R, Schettini J, Raiden S, Geffner J: Bacterial DNA activates human neutrophils by a CpG-independent pathway. Eur J Immunol. 2003 Nov;33(11):3164-74. Pubmed
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

3. Toll-like receptor 9

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
Toll-like receptor 9 Q9NR96 Details

References:

  1. Sun S, Rao NL, Venable J, Thurmond R, Karlsson L: TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets. 2007 Dec;6(4):223-35. Pubmed
  2. Trevani AS, Chorny A, Salamone G, Vermeulen M, Gamberale R, Schettini J, Raiden S, Geffner J: Bacterial DNA activates human neutrophils by a CpG-independent pathway. Eur J Immunol. 2003 Nov;33(11):3164-74. Pubmed

Enzymes

1. Cytochrome P450 2D6

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2D6 P10635 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed
  2. Somer M, Kallio J, Pesonen U, Pyykko K, Huupponen R, Scheinin M: Influence of hydroxychloroquine on the bioavailability of oral metoprolol. Br J Clin Pharmacol. 2000 Jun;49(6):549-54. Pubmed

Comments
comments powered by Disqus
Drug created on August 29, 2007 14:00 / Updated on April 29, 2014 11:05